| James Childers, RPH,LDE | |
|
150 W Lowry Ln Ste 190, Lexington, KY 40503-3030 | |
| (859) 276-2119 | |
| (859) 276-2938 |
| Full Name | James Childers |
|---|---|
| Gender | Male |
| Speciality | Pharmacist - Pharmacist Clinician (phc)/ Clinical Pharmacy Specialist |
| Location | 150 W Lowry Ln Ste 190, Lexington, Kentucky |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023617917 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1835P0018X | Pharmacist - Pharmacist Clinician (phc)/ Clinical Pharmacy Specialist | 011055 (Kentucky) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| James Childers, RPH,LDE 150 W Lowry Ln Ste 190, Lexington, KY 40503-3030 Ph: (859) 276-2119 | James Childers, RPH,LDE 150 W Lowry Ln Ste 190, Lexington, KY 40503-3030 Ph: (859) 276-2119 |
News Archive
According to new research, British people drink more alcohol on a night out than any of their Western European neighbours.
Acorda Therapeutics, Inc. today announced plans to initiate a Phase 1 single-dose clinical trial of the Company's compound, Glial Growth Factor 2 (GGF2), in patients with heart failure in mid-2010, based on an IND filed with the U.S. Food and Drug Administration (FDA) on March 19, 2010. GGF2 has been shown to protect heart muscle and restore cardiac function in preclinical models of heart failure, myocardial infarction and cardiotoxicity.
Coinciding with the annual European Respiratory Society Congress, ERS 2012, SPIRIVA (tiotropium), the first once-daily long-acting inhaled anticholinergic maintenance treatment for patients with Chronic Obstructive Pulmonary Disease (COPD) will mark its 10th anniversary since launch.
Neogenix Oncology, Inc. (Neogenix) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's product candidate ensituximab (monoclonal antibody NPC-1C) for the treatment of pancreatic cancer. The Company initiated in December 2009 a multi-center Phase I clinical trial of ensituximab (NPC-1C) for the treatment of advanced pancreatic and colorectal cancer.
› Verified 4 days ago
Dr. Teresa Connealy German, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1101 Veterans Dr, Lexington, KY 40502 Phone: 859-281-3939 | |
Kevin Anthony Fosso, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3051 Kirklevington Dr, Apt 89, Lexington, KY 40517 Phone: 859-523-0987 | |
Dr. Elizabeth Brown Autry, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 740 S Limestone, Lexington, KY 40536 Phone: 859-218-2509 Fax: 859-323-3499 | |
Mrs. Kathy J Lovell, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1101 Veterans Dr, Lexington, KY 40502 Phone: 859-281-4976 | |
Mr. Michael D Hislope, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1 Saint Joseph Dr, Lexington, KY 40504 Phone: 859-313-4443 Fax: 859-313-3070 | |
Mr. Danny Lee Perry, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1740 Nicholasville Rd, Lexington, KY 40503 Phone: 859-260-6659 | |
Tristan Alexander Carnes, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1101 Veterans Dr, Lexington, KY 40502 Phone: 859-233-4511 |